Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 2/20 | 0.52 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.52 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.52 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.52 |
| ▸ | ITGAV | P06756 | 1/20 | 0.52 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.52 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.52 |
| ▸ | ITGAL | P20701 | 1/20 | 0.52 |
| ▸ | SLC6A1 | P30531 | 4/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.41 |
| ▸ | SLC6A12 | P48065 | 4/20 | 0.41 |
| ▸ | SLC6A11 | P48066 | 4/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.41 |
| ▸ | GABRR1 | P24046 | 3/20 | 0.41 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.41 |
| ▸ | SLC6A13 | Q9NSD5 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 4/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8831747 | 0.76 | — | — | |
| SCHEMBL28296227 | 0.74 | — | — | |
| SCHEMBL23802787 | 0.74 | ITGB3 (0.50) | ITGB1ITGA5ITGB3ITGB2ITGAV | |
| SCHEMBL23802737 | 0.74 | ITGB3 (0.50) | ITGB1ITGA5ITGB3ITGB2ITGAV | |
| SCHEMBL10153595 | 0.74 | — | — | |
| SCHEMBL31324256 | 0.72 | ITGB1 (0.55) | ITGB1ITGA5ITGB3ITGB2ITGAV | |
| SCHEMBL27598253 | 0.72 | ITGB1 (0.55) | ITGB1ITGA5ITGB3ITGB2ITGAV | |
| SCHEMBL6600860 | 0.72 | ITGB1 (0.55) | ITGB1ITGA5ITGB3ITGB2ITGAV | |
| SCHEMBL6607266 | 0.72 | ITGB1 (0.55) | ITGB1ITGA5ITGB3ITGB2ITGAV | |
| SCHEMBL17459867 | 0.69 | EGLN1 (0.47) | GABRA5GABRB2GABRA1GABRR1GABRA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054460-A1 | Piperazine derivatives and methods of use | CHEN JIAN J | 2009-02-26 | — | — | US | disclosed |
| US-7393852-B2 | Piperazine derivatives and methods of use | AMGEN INC. (US) | 2008-07-01 | — | — | US | disclosed |
| EP-1656355-B1 | PIPERAZINE DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2008-03-12 | — | — | EP | disclosed |
| EP-1878728-A2 | Derivatives of piperazine and higher homologues thereof for the treatment of inflammation-related disorders | Amgen Inc. (US) | 2008-01-16 | — | — | EP | disclosed |
| CN-1849121-A | Piperazine derivatives as bradyknin antagonist | AMGEN INC (US) | 2006-10-18 | — | — | CN | disclosed |
| US-20060178370-A1 | Ketopiperazine derivatives as bradykinin antagonists | MERCK & CO., INC. | 2006-08-10 | — | — | US | disclosed |
| EP-1656355-A2 | PIPERAZINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2006-05-17 | — | — | EP | disclosed |
| WO-2005061467-A2 | PIPERAZINE DERIVATIVES AS BRADYKININ ANTAGONISTS | AMGEN INC. (US) | 2005-07-07 | — | — | WO | disclosed |
| US-20050014749-A1 | analgesics; antiinflammatory agents; antiarthritic agents;Alzheimer's disease; cirrhosis; antiallergens; antihistamines ; anticancer agents; vision defects | AMGEN INC. | 2005-01-20 | — | — | US | disclosed |
| WO-2004083173-A2 | KETOPIPERAZINE DERIVATIVES AS BRADYKININ ANTAGONISTS | MERCK & CO., INC. (US) | 2004-09-30 | — | — | WO | disclosed |
| WO-2003013740-A1 | 4- AND 5-AMINO-α, β UNSTATURATED ESTER SOLID SUPPORT TEMPLATES, METHOD OF PREPARATION AND FOR USING THE SAME | ADVANCED SYNTECH, LLC (US) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054460-A1 | Piperazine derivatives and methods of use | PTGES, PTGES2, PTGIS | ITGB1 3570/4885ITGA5 2134/4885ITGB3 2913/4885 |
| US-20060178370-A1 | Ketopiperazine derivatives as bradykinin antagonists | BDKRB1, BDKRB2, KLKB1 | ITGB1 2251/4885ITGA5 3818/4885ITGB3 3466/4885 |
| US-20050014749-A1 | analgesics; antiinflammatory agents; antiarthritic agents;Alzheimer's disease; cirrhosis; antiallergens; antihistamines ; anticancer agents; vision defects | ACHE, TNF, BCHE | ITGB1 3287/4885ITGA5 2460/4885ITGB3 3329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.